The Contribution of Circulating Tumor DNA in Liquid Biopsy for Cancer Diagnosis

Mouad Benhassine^*
*Correspondence: Mouad Benhassine, Department of Tumor Biology, Higher Institute of Nursing Professions and Health Techniques, Morocco, Email:

Introduction

Cancer remains one of the leading causes of death worldwide and early detection plays a critical role in improving the prognosis and outcomes of patients. Traditional diagnostic methods, including tissue biopsies, are often invasive, costly and sometimes inaccessible, limiting their ability to provide real-time insights into cancer progression or response to treatment. In recent years, the development of liquid biopsy has revolutionized cancer diagnosis. This non-invasive technique involves the analysis of blood samples to detect genetic material associated with tumors, primarily circulating tumor DNA (ctDNA). ctDNA consists of DNA fragments released into the bloodstream by tumor cells as they die or undergo necrosis. As the tumor grows and changes, ctDNA can reflect the tumor's genetic alterations, making it a valuable tool for diagnosing cancer, monitoring treatment and tracking disease recurrence. This paper explores the contribution of ctDNA in liquid biopsy, highlighting its importance in cancer diagnosis, its clinical applications, the challenges associated with its use and its potential for shaping the future of cancer care [1].

Description

The fundamental principle behind liquid biopsy is the detection of ctDNA, a form of DNA shed into the bloodstream by tumor cells. ctDNA is present in small amounts, often in a mixture with normal DNA, making its detection challenging. However, as tumors grow, the concentration of ctDNA in the blood increases, offering a valuable source of information for diagnosing cancer. ctDNA can provide insight into the tumor's genetic makeup, including mutations, amplifications, deletions and other alterations specific to the cancer. Unlike traditional tissue biopsies, which often require invasive procedures, liquid biopsy provides a non-invasive means to detect and monitor cancer in real-time [2]. Despite the numerous benefits of ctDNA-based liquid biopsy, several challenges remain. One of the main challenges is the low concentration of ctDNA, particularly in early-stage cancers or small tumors. The sensitivity of ctDNA testing depends on the amount of ctDNA present in the bloodstream, which can vary depending on the tumor's size, type and location. Therefore, detecting ctDNA in early-stage cancers or in patients with small tumors can be difficult, necessitating highly sensitive and precise techniques. Furthermore, not all mutations or alterations in the tumor are shed into the bloodstream. In some cases, the ctDNA levels may not be sufficient to reflect the full range of genetic alterations present in the tumor, leading to false negatives or incomplete results.

Conclusion

In conclusion, circulating tumor DNA has emerged as a powerful biomarker in the field of liquid biopsy, offering a non-invasive and dynamic method for cancer diagnosis and monitoring. The ability to detect ctDNA in blood samples allows for early cancer detection, real-time monitoring of treatment response and the identification of minimal residual disease, all of which are critical factors in improving cancer outcomes. While challenges such as low ctDNA concentration, tumor heterogeneity and the lack of standardization persist, ongoing research and technological advancements are expected to overcome these obstacles and improve the clinical utility of ctDNA-based liquid biopsy. The future of cancer care lies in personalized, precision medicine and ctDNA plays a pivotal role in enabling this shift. As liquid biopsy becomes increasingly integrated into routine clinical practice, it holds the potential to revolutionize cancer diagnostics and treatment, leading to more effective and targeted therapies for patients worldwide.

References

1. Fernández-Lázaro, Diego, Juan Luis García Hernández, Alberto Caballero García and Aurora Caballero del Castillo, et al. “Clinical perspective and translational oncology of liquid biopsy.” Diagnostics 10 (2020): 443.

Google Scholar, Crossref, Indexed at

2. Anvari, Maryam Sotoudeh, Atoosa Gharib, Maryam Abolhasani and Aileen Azari-Yam, et al. “Pre-analytical practices in the molecular diagnostic tests, a concise review.” Iran J Pathol 16 (2021): 1.

Google Scholar, Crossref